1. Generics Bulletin
  2. >>Business
  3. >>Deals

Aspen Confirms ‘Material’ Offers For API Unit Remain Under Consideration

Chemicals And Biochem Segments Saw Increased Sales In FY21; Higher Costs Bit

 
• By Dean Rudge

Aspen Pharmacare is continuing to ponder offloading another part of its operations, with bids under consideration for its significant API business units. The company only recently sold a basket of products in South Africa to Acino.

running athletic race track with blending South Africa flag
Aspen APIs include peptides, biochemicals, hormones and steroids • Source: Shutterstock

Aspen Pharmacare is continuing to weigh offers for its active pharmaceutical ingredients business, after recently confirming receipt of two “unsolicited offers” and indicating that a sale “may have a material effect on the price of Aspen’s securities.”

The South African firm confirmed that it had “decided to embark on a structured process to facilitate offers for all...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Corapharm Deal Offers South-East Europe Opportunity For mAbxience

 
• By Dave Wallace

Hot on the heels of a recent alliance in Italy, biosimilars developer mAbxience has struck another deal – this time partnering with Corapharm in south-east Europe.

Big In Japan: Samsung Bioepis Looks To Increase Presence With Nipro Partnership

 
• By Dean Rudge

Ahead of being spun out of its parent company Samsung Biologics later this year, Samsung Bioepis has struck an agreement to bolster its presence in another Asian market and one of the largest global pharma markets.

Zydus Strikes Landmark $141m Agreement To Break Into Global CDMO Business

 
• By Dean Rudge

Zydus Lifesciences said it would be able to leverage supply chain dynamics and a “favorable geopolitical environment” to expand its reach in the US and globally as it penned a trio of agreements to plant its flag in the global CDMO space.

Dr Reddy’s And Alvotech Team Up On Keytruda Rival

 
• By Dave Wallace

After previously partnering on denosumab, Alvotech and Dr Reddy’s have announced a further alliance to co-develop a biosimilar version of Keytruda (pembrolizumab).

More from Business

Zydus Strikes Landmark $141m Agreement To Break Into Global CDMO Business

 
• By Dean Rudge

Zydus Lifesciences said it would be able to leverage supply chain dynamics and a “favorable geopolitical environment” to expand its reach in the US and globally as it penned a trio of agreements to plant its flag in the global CDMO space.

Dr Reddy’s And Alvotech Team Up On Keytruda Rival

 
• By Dave Wallace

After previously partnering on denosumab, Alvotech and Dr Reddy’s have announced a further alliance to co-develop a biosimilar version of Keytruda (pembrolizumab).

Formycon And Fresenius Launch Partnered Stelara Rival In Canada

 
• By Adam Zamecnik

Several years after the initial signing of their agreement, Formycon and Fresenius Kabi announced the launch of their Stelara biosimilar Otulfi in Canada, adding another key market to their list.